• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:刘伟,吴正波,权宋潇,范宗静,崔杰,吴旸,林泉.基于网络药理学和分子对接探讨西洋参-丹参“异病同治”动脉粥样硬化和血栓形成的作用机制[J].药学研究,2026,45(5):494-501,561[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1822次   下载 823次 本文二维码信息
码上扫一扫!
基于网络药理学和分子对接探讨西洋参-丹参“异病同治”动脉粥样硬化和血栓形成的作用机制
刘伟,吴正波,权宋潇,范宗静,崔杰,吴旸,林泉
字体:加大+|默认|缩小-
(北京中医药大学东方医院心血管科,北京 100078)
摘要:
目的 通过网络药理学和分子对接技术探讨西洋参-丹参“异病同治”动脉粥样硬化和血栓形成的作用机制。方法 在TCMSP数据库检索西洋参和丹参的活性成分和作用靶点,通过Uniprot数据库规范靶点名称。在GeneCards、OMIM、TTD和DisGeNET数据库检索动脉粥样硬化和血栓形成的疾病靶点。取交集获得共同靶点,构建“中药-共同靶点-疾病”网络和PPI网络。利用 MetaScape数据库进行GO和KEGG通路富集分析。使用CB-DOCK2平台进行分子对接。结果 筛选出中药活性成分76个、活性成分潜在靶点993个,“异病同治”共同靶点80个,GO分析结果发现271个BP、57个CC、103个MF,KEGG通路富集分析结果发现165条信号通路。核心活性成分包括木犀草素、丹参酮IIA、二氢丹参内酯、β-谷甾醇等,核心治疗靶点包括IL-6、TNF、IL-1β、Akt1、TP53、MMP9、PTGS2等,作用信号通路包括脂质和动脉粥样硬化、AGE-RAGE信号通路、PI3K-Akt信号通路等,并且发现其他疾病相关信号通路在本领域潜在的研究价值。核心活性成分与核心靶点之间的结合性均较好,其中丹参酮IIA与TNF之间的结合力最强。结论 西洋参-丹参“异病同治”动脉粥样硬化和血栓形成具有多成分、多靶点、多通路的治疗特点,证实了核心活性成分与核心治疗靶点较强的结合力,为其临床应用和进一步研究提供了理论依据。
关键词:  西洋参  丹参  动脉粥样硬化  血栓形成  网络药理学  异病同治
DOI:10.13506/j.cnki.jpr.2026.05.003
基金项目:北京市丰台区卫生健康系统科研项目(No.2023-58);河北省中医药管理局科研计划项目(No.B2025041);中央高水平中医医院临床科研业务费资助项目(No.DFGZRA-2024GJRC001);中央高校基本科研业务费专项资金项目(No.2022-JYB-XJSJJ-073)
收稿日期:2025-02-14   修回日期:2025-04-13   出版日期:2026-05-29
Exploration of the mechanism of Panax quinquefolium L.-Salvia Miltiorrhiza Bge. in treating atherosclerosis and thrombosis with the concept of “Different Diseases with the Same Treatment” based on network pharmacology and molecular docking technology
LIU Wei,WU Zhengbo,QUAN Songxiao,FAN Zongjing,CUI Jie,WU Chang,LIN Quan
(Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China)
Abstract:
Objective To explore the mechanism of treating atherosclerosis and thrombosis in Panax quinquefolium L.-Salvia Miltiorrhiza Bge. by network pharmacology combined with molecular docking technology.Methods The TCMSP database was searched for active ingredients and targets of action of Panax quinquefolium L.-Salvia Miltiorrhiza Bge., and target names were standardised through the Uniprot database. The GeneCards, OMIM, TTD and DisGeNET databases were used to search for disease targets of atherosclerosis and thrombosis. The intersections were used to obtain common targets, and the ‘Chinese medicine-common target-disease’ network and PPI network were constructed. GO and KEGG pathway enrichment analyses were performed using MetaScape database. Molecular docking was performed using CB-DOCK2 platform. Results We screened 76 active ingredients of Chinese medicine, 993 potential targets of active ingredients, 80 common targets of ‘different diseases with the same treatment’, 271 BP, 57 CC, 103 MF in GO analysis, and 165 signalling pathways in KEGG pathway enrichment analysis. The core active ingredients included luteolin, tanshinone iia, dihydrotanshinlactone, beta-sitosterol, etc., the core therapeutic targets included IL-6, TNF, IL-1β, Akt1, TP53, MMP9, PTGS2, etc., and the action signalling pathways included lipid and atherosclerosis, AGE-RAGE signaling pathway, PI3K-Akt signaling pathway, etc., and found that other disease-related signaling pathways are potentially valuable for research in this field. The binding between the core active ingredients and the core targets were all good, with the strongest binding between tanshinone IIA and TNF.Conclusion The treatment of atherosclerosis and thrombosis by Panax quinquefolium L.-Salvia Miltiorrhiza Bge. has the therapeutic characteristics of multi-components, multi-targets and multi-pathways, which confirms the strong combination of the core active ingredients and the core therapeutic targets, and provides theoretical basis for its clinical application and further research.
Key words:  Panax quinquefolium L.  Salvia Miltiorrhiza Bge.  Atherosclerosis  Thrombosis  Network pharmacology  Different diseases with the same treatment
今日访问量:2271    总访问量:55338612
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司